Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Next generation immune-checkpoints for cancer therapy.

Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D.

J Thorac Dis. 2018 May;10(Suppl 13):S1581-S1601. doi: 10.21037/jtd.2018.02.79. Review.

2.

Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients.

Iasevoli F, D'Ambrosio L, Notar Francesco D, Razzino E, Buonaguro EF, Giordano S, Patterson TL, de Bartolomeis A.

Schizophr Res. 2018 Jun 19. pii: S0920-9964(18)30364-5. doi: 10.1016/j.schres.2018.06.030. [Epub ahead of print]

PMID:
29934250
3.

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800934. doi: 10.1183/13993003.00934-2018. Print 2018 Jul. No abstract available.

PMID:
29903862
4.

Tuberculosis elimination: where are we now?

Matteelli A, Rendon A, Tiberi S, Al-Abri S, Voniatis C, Carvalho ACC, Centis R, D'Ambrosio L, Visca D, Spanevello A, Battista Migliori G.

Eur Respir Rev. 2018 Jun 13;27(148). pii: 180035. doi: 10.1183/16000617.0035-2018. Print 2018 Jun 30.

5.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. Portuguese, English.

6.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
7.

Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.

Munoz-Torrico M, Salazar MA, Millán MJM, Martínez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, Visca D, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702267. doi: 10.1183/13993003.02267-2017. Print 2018 Mar. No abstract available.

PMID:
29567721
8.

Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Centis R, Alffenaar JW, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702187. doi: 10.1183/13993003.02187-2017. Print 2018 Mar. No abstract available.

PMID:
29567720
9.

Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.

Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, Grignani G, Cesari M, Longhi A, Abate ME, Paioli A, Szucs Z, D'ambrosio L, Scotlandi K, Fagioli F, Asaftei S, Ferrari S.

Acta Oncol. 2018 Mar 13:1-7. doi: 10.1080/0284186X.2018.1449250. [Epub ahead of print]

PMID:
29533113
10.

New drugs and perspectives for new anti-tuberculosis regimens.

Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24.

11.

Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.

Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.

Curr Opin Pulm Med. 2018 May;24(3):244-252. doi: 10.1097/MCP.0000000000000477.

PMID:
29470252
12.

Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma.

Tseng WW, Tsao-Wei DD, Callegaro D, Grignani G, D'Ambrosio L, Bonvalot S, Ethun CG, Cardona K, Mullen JT, Canter RJ, Mullinax JE, Gonzalez RJ, van Coevorden F, Albertsmeier M, Dhanireddy KK, Renne SL, Gronchi A; A Collaborative Effort from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).

Eur J Surg Oncol. 2018 Jun;44(6):810-815. doi: 10.1016/j.ejso.2018.01.086. Epub 2018 Feb 5.

PMID:
29452860
13.

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA.

Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19.

14.

Diagnostic performances of the Xpert MTB/RIF in Brazil.

Silva DR, Sotgiu G, D'Ambrosio L, Pereira GR, Barbosa MS, Dias NJD, Saderi L, Centis R, Migliori GB.

Respir Med. 2018 Jan;134:12-15. doi: 10.1016/j.rmed.2017.11.012. Epub 2017 Nov 21.

PMID:
29413498
15.

Sharing is caring: The potential of the sharing economy to support aging in place.

Miller J, Ward C, Lee C, D'Ambrosio L, Coughlin J.

Gerontol Geriatr Educ. 2018 Jan 24:1-23. doi: 10.1080/02701960.2018.1428575. [Epub ahead of print]

PMID:
29364788
16.

Tuberculosis elimination: a dream or a reality? The case of Oman.

Al Yaquobi F, Al-Abri S, Al-Abri B, Al-Abaidani I, Al-Jardani A, D'Ambrosio L, Centis R, Matteelli A, Manissero D, Migliori GB.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702027. doi: 10.1183/13993003.02027-2017. Print 2018 Jan. No abstract available.

PMID:
29326321
17.

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

D'Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, Payen MC, Saavedra Herrera N, Salazar Lezama MA, Skrahina A, Tadolini M, Tiberi S, Veziris N, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):132-141. doi: 10.1016/j.rppnen.2017.10.005. Epub 2017 Dec 8.

18.

Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey.

Amicosante M, D'Ambrosio L, Munoz M, Mello FCQ, Tebruegge M, Chegou NN, Seghrouchni F, Centis R, Goletti D, Bothamley G, Migliori GB; TB Diagnostic Survey Working Group.

J Bras Pneumol. 2017 Sep-Oct;43(5):380-392. doi: 10.1590/S1806-37562017000000219. English, Portuguese.

19.

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.

Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701462. doi: 10.1183/13993003.01462-2017. Print 2017 Nov. No abstract available.

PMID:
29146605
20.

Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?

Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Int J Infect Dis. 2017 Dec;65:133-134. doi: 10.1016/j.ijid.2017.10.019. Epub 2017 Nov 6. No abstract available.

21.

Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.

Luzzati R, Migliori GB, Zignol M, Cirillo DM, Maschio M, Tominz R, Ventura G, Patussi V, D'Ambrosio L, Centis R, Michieletto F, Trovato A, Salton F, Busetti M, Di Santolo M, Raviglione M, Confalonieri M.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701414. doi: 10.1183/13993003.01414-2017. Print 2017 Nov. No abstract available.

PMID:
29097434
22.

CHD2 mutations: Only epilepsy? Description of cognitive and behavioral profile in a case with a new mutation.

Bernardo P, Galletta D, Iasevoli F, D'Ambrosio L, Troisi S, Gennaro E, Zara F, Striano S, de Bartolomeis A, Coppola A.

Seizure. 2017 Oct;51:186-189. doi: 10.1016/j.seizure.2017.09.001. Epub 2017 Sep 6. No abstract available.

PMID:
28910737
23.

Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.

de Bartolomeis A, Prinzivalli E, Callovini G, D'Ambrosio L, Altavilla B, Avagliano C, Iasevoli F.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:356-366. doi: 10.1016/j.pnpbp.2017.09.002. Epub 2017 Sep 5.

PMID:
28887181
24.

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, Esposito S, Migliori GB.

J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16. Review.

25.

Understanding the multidrug-resistant tuberculosis epidemic in China.

Centis R, D'Ambrosio L, Migliori GB.

Int J Tuberc Lung Dis. 2017 Sep 1;21(9):955. doi: 10.5588/ijtld.17.0438. No abstract available.

PMID:
28826442
26.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Emerg Infect Dis. 2017 Oct;23(10). doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

27.

A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium.

D'Ambrosio L, Tadolini M, Centis R, Chalmers JD, Migliori GB.

Indian J Med Res. 2017 Mar;145(3):261-263. doi: 10.4103/ijmr.IJMR_37_17. No abstract available.

28.

Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences.

Dara M, Sulis G, Centis R, D'Ambrosio L, de Vries G, Douglas P, Garcia D, Jansen N, Zuroweste E, Migliori GB.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):727-736. doi: 10.5588/ijtld.16.0940.

PMID:
28633696
29.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

PMID:
28529205
30.

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.

Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G.

Mol Cancer. 2017 Apr 28;16(1):86. doi: 10.1186/s12943-017-0652-5.

31.

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.

D'Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatis D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, Grignani G.

Eur J Cancer. 2017 Jun;78:122-132. doi: 10.1016/j.ejca.2017.03.025. Epub 2017 Apr 24.

PMID:
28448856
32.

Alpha-fetoprotein elevation in NUT midline carcinoma: a case report.

D'Ambrosio L, Palesandro E, Moretti M, Pelosi G, Fabbri A, Carnevale Schianca F, Aglietta M, Grignani G.

BMC Cancer. 2017 Apr 13;17(1):266. doi: 10.1186/s12885-017-3262-0.

33.

Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.

Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Braga JU, Arakaki Sanchez D, Dockhorn F, Centis R, Migliori GB.

Eur Respir J. 2017 Apr 12;49(4). pii: 1602309. doi: 10.1183/13993003.02309-2016. Print 2017 Apr. No abstract available.

PMID:
28404651
34.

World TB Day 2017: Strengthening the fight against TB.

Solovic I, Centis R, D'Ambrosio L, Visca D, Battista Migliori G.

Presse Med. 2017 Mar;46(2 Pt 2):e1-e4. doi: 10.1016/j.lpm.2017.02.002. No abstract available.

PMID:
28336002
35.

Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.

Pontali E, D'Ambrosio L, Centis R, Sotgiu G, Migliori GB.

Eur Respir J. 2017 Mar 22;49(3). pii: 1700146. doi: 10.1183/13993003.00146-2017. Print 2017 Mar. No abstract available.

PMID:
28331046
36.

Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.

Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Braga JU, Galesi VM, Barreira D, Sanchez DA, Dockhorn F, Centis R, Caminero JA, Migliori GB.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602445. doi: 10.1183/13993003.02445-2016. Print 2017 Mar.

PMID:
28331044
37.

Tuberculosis elimination and the challenge of latent tuberculosis.

Matteelli A, Sulis G, Capone S, D'Ambrosio L, Migliori GB, Getahun H.

Presse Med. 2017 Mar;46(2 Pt 2):e13-e21. doi: 10.1016/j.lpm.2017.01.015. Epub 2017 Mar 6. Review.

PMID:
28279508
38.

How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.

Marchesi E, Cagnazzo C, Quattrini I, Leopardi MP, Villa C, Grignani G, D'Ambrosio L, Stacchiotti S, Casali PG, Picci P.

Clin Sarcoma Res. 2017 Feb 28;7:4. doi: 10.1186/s13569-017-0068-4. eCollection 2017.

39.

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.

Int J Mol Sci. 2017 Feb 7;18(2). pii: E341. doi: 10.3390/ijms18020341. Review.

40.

Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients.

Longhi A, Bielack SS, Grimer R, Whelan J, Windhager R, Leithner A, Gronchi A, Biau D, Jutte P, Krieg AH, Klenke FM, Grignani G, Donati DM, Capanna R, Casanova J, Gerrand C, Bisogno G, Hecker-Nolting S, De Lisa M, D'Ambrosio L, Willegger M, Scoccianti G, Ferrari S.

Eur J Cancer. 2017 Mar;74:9-16. doi: 10.1016/j.ejca.2016.12.016. Epub 2017 Feb 3.

PMID:
28167373
41.

Preventive behaviors and perceptions of influenza vaccination among a university student population.

Hashmi S, D'Ambrosio L, Diamond DV, Jalali MS, Finkelstein SN, Larson RC.

J Public Health (Oxf). 2016 Dec 2;38(4):739-745. doi: 10.1093/pubmed/fdv189. No abstract available.

PMID:
28158761
42.

Target regimen profiles for treatment of tuberculosis: a WHO document.

Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M.

Eur Respir J. 2017 Jan 25;49(1). pii: 1602352. doi: 10.1183/13993003.02352-2016. Print 2017 Jan. No abstract available.

43.

Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.

Muñoz-Torrico M, Caminero-Luna J, Migliori GB, D'Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, Torres-Cruz A, Flores-Vergara H, Martínez-Mendoza D, García-Sancho C, Centis R, Salazar-Lezama MÁ, Pérez-Padilla R.

Arch Bronconeumol. 2017 May;53(5):245-250. doi: 10.1016/j.arbres.2016.10.021. Epub 2017 Jan 11. English, Spanish.

44.
45.

Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data.

Muñoz-Torrico M, Caminero Luna J, Migliori GB, D'Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, Torres-Cruz A, Flores-Ergara H, Martínez-Mendoza D, García-Sancho C, Centis R, Salazar-Lezama MÁ, Pérez-Padilla R.

Rev Port Pneumol (2006). 2017 Jan - Feb;23(1):27-30. doi: 10.1016/j.rppnen.2016.11.009. Epub 2016 Dec 31.

46.

Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.

Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D'Ambrosio L, Vassallo E, Fizzotti M, Nesi F, Gioeni L, Berger M, Polo A, Gammaitoni L, Becco P, Giraudo L, Mangioni M, Sangiolo D, Grignani G, Rota-Scalabrini D, Sottile A, Fagioli F, Aglietta M.

Biol Blood Marrow Transplant. 2017 Mar;23(3):459-466. doi: 10.1016/j.bbmt.2016.12.636. Epub 2016 Dec 27.

47.

Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?

Centis R, D'Ambrosio L, Zumla A, Migliori GB.

Int J Infect Dis. 2017 Mar;56:30-33. doi: 10.1016/j.ijid.2016.11.416. Epub 2016 Dec 1.

48.

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Rendon A, Tiberi S, Scardigli A, D'Ambrosio L, Centis R, Caminero JA, Migliori GB.

J Thorac Dis. 2016 Oct;8(10):2666-2671. No abstract available.

49.

Time to review treatment of isoniazid-resistant tuberculosis?

D'Ambrosio L, Migliori GB, Sotgiu G.

Lancet Infect Dis. 2017 Feb;17(2):127-128. doi: 10.1016/S1473-3099(16)30381-4. Epub 2016 Nov 17. No abstract available.

PMID:
27865889
50.

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.

Harausz EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, Hesseling AC, Achar J, Bernheimer J, Cruz AT, D'Ambrosio L, Detjen A, Graham SM, Hughes J, Jonckheere S, Marais BJ, Migliori GB, McKenna L, Skrahina A, Tadolini M, Wilson P, Furin J; Sentinel Project on Pediatric Drug-Resistant Tuberculosis.

Am J Respir Crit Care Med. 2017 May 15;195(10):1300-1310. doi: 10.1164/rccm.201606-1227CI. Review.

Supplemental Content

Loading ...
Support Center